

業績目録 (令和2年)

教室・部門名 分子診断・治療医学

I 著書

II 総説

1. 谷脇雅史, 松本洋典, 名越久朗. 特集 多発性骨髄腫. 骨髄腫ゲノム異常の多様性と臨床応用—ヌクレオーム解析へ—. カレントセラピー 38(6):16-22, 2020
2. 谷脇雅史, 松本洋典, 知念良顕, 名越久朗. II. 造血器腫瘍の基礎. 1.造血器発がんリスク. 染色体異常. 造血器腫瘍学 (第2版)—基礎と臨床の最新研究動向—. 日本臨床 78巻増刊号 (通巻 1182号), pp.51-58, 2020

III 原著

1. Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, Shpilberg O, Grosicki S, Špička I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Matsumoto M, Wu KL, Anderson KC, Jou YM, Ganetsky A, Singhal AK, Richardson PG. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. *Blood Cancer J.* 2020 Sep 4;10(9):91. doi: 10.1038/s41408-020-00357-4. (IF= 6.510)
2. Matsumoto Y, Chinen Y, Shimura Y, Nagoshi H, Sasaki N, Muramatsu A, Kuriyama K, Ohshiro M, Hirakawa Y, Iwai T, Uchiyama H, Taki T, Horiike S, Kuroda J, Taniwaki M. Recurrent intragenic exon rearrangements of SOBP and AUTS2 in non-Hodgkin B-cell lymphoma. *Int J Hematol.* 2020 Jan;111(1):75-83. doi: 10.1007/s12185-019-02766-z. (IF= 2.350)
3. Matsumoto Y, Masuda T, Nishimura A, Horie H, Harada K, Yoshida M, Shimura K, Kaneko H, Taniwaki M. A case of AL amyloidosis associated with follicular lymphoma with plasmacytic differentiation. *Int J Hematol.* 2020 Feb;111(2):317-323. doi: 10.1007/s12185-019-02734-7. (IF= 2.350)
4. Yoshida M, Matsumoto Y, Horie H, Nishimura S, Shimura K, Kaneko H, Taniwaki

- M. Endoscopic findings in a patient with idiopathic/immune thrombocytopenic purpura: Gastrointestinal bleeding caused by Dieulafoy's lesion. *Indian J Gastroenterol.* 2020 Feb;39(1):102-103. doi: 10.1007/s12664-019-01001-1. (IF= 1.080)
5. Isa R, Uoshima N, Takahashi R, Nakano-Akamatsu S, Kawata E, Kaneko H, Shimura K, Kamitsuji Y, Takimoto-Shimomura T, Mizutani S, Chinen Y, Ohshiro M, Fujino T, Kawaji Y, Uchiyama H, Sasaki N, Tsukamoto T, Shimura Y, Kobayashi T, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group investigators. Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma. *Ann Hematol.* 2020 Jan;99(1):137-145. doi: 10.1007/s00277-019-03859-9. (血液内科学との共同研究) (IF= 2.840)
 6. Nishiyama D, Chinen Y, Isa R, Fujibayashi Y, Kuwahara-Ota S, Yamaguchi J, Takimoto-Shimomura T, Matsumura-Kimoto Y, Tsukamoto T, Shimura Y, Kobayashi T, Horiike S, Taniwaki M, Handa H, Kuroda J. EWSR1 overexpression is a pro-oncogenic event in multiple myeloma. *Int J Hematol.* 2020 Oct 23. doi: 10.1007/s12185-020-03027-0. (血液内科学との共同研究) (IF= 2.350)
 7. Chinen Y, Tanba K, Takagi R, Uchiyama H, Uoshima N, Shimura K, Fuchida SI, Kiyota M, Nakao M, Tsukamoto T, Shimura Y, Kobayashi T, Horiike S, Wada K, Shimazaki C, Kaneko H, Kobayashi Y, Taniwaki M, Yokota I, Kuroda J; Kyoto Clinical Hematology Study Group investigators. Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma. *Leuk Lymphoma.* 2020 Aug 27:1-9. doi: 10.1080/10428194.2020.1811862. (血液内科学との共同研究) (IF= 2.640)
 8. Fujibayashi Y, Isa R, Nishiyama D, Sakamoto-Inada N, Kawasumi N, Yamaguchi J, Kuwahara-Ota S, Matsumura-Kimoto Y, Tsukamoto T, Chinen Y, Shimura Y, Kobayashi T, Horiike S, Taniwaki M, Handa H, Kuroda J. Aberrant BUB1 overexpression promotes mitotic segregation errors and chromosomal instability in multiple myeloma. *Cancers (Basel).* 2020 Aug 6;12(8):2206. doi: 10.3390/cancers12082206. (血液内科学との共同研究) (IF= 6.370)
 9. Kuwahara-Ota S, Shimura Y, Steinebach C, Isa R, Yamaguchi J, Nishiyama D,

Fujibayashi Y, Takimoto-Shimomura T, Mizuno Y, Matsumura-Kimoto Y, Tsukamoto T, Chinen Y, Kobayashi T, Horiike S, Taniwaki M, Gütschow M, Kuroda J. Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma. *Br J Haematol.* 2020 Jun 19. doi: 10.1111/bjh.16881. (血液内科学との共同研究) (IF= 5.020)

10. Matsumura-Kimoto Y, Tsukamoto T, Shimura Y, Chinen Y, Tanba K, Kuwahara-Ota S, Fujibayashi Y, Nishiyama D, Isa R, Yamaguchi J, Kawaji-Kanayama Y, Kobayashi T, Horiike S, Taniwaki M, Kuroda J. Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma. *Cancer Med.* 2020 Jul;9(14):5185-5199. doi: 10.1002/cam4.3136. (血液内科学との共同研究) (IF= 3.460)
11. Chinen Y, Tsukamoto T, Maegawa-Matsui S, Matsumura-Kimoto Y, Takimoto-Shimomura T, Tanba K, Mizuno Y, Fujibayashi Y, Kuwahara-Ota S, Shimura Y, Kobayashi T, Horiike S, Taniwaki M, Kuroda J. Tumor-specific transcript variants of cyclin D1 in mantle cell lymphoma and multiple myeloma with chromosome 11q13 abnormalities. *Exp Hematol.* 2020 Apr;84:45-53.e1. doi: 10.1016/j.exphem.2020.02.004. (血液内科学との共同研究) (IF= 2.350)
12. Tsukamoto T, Nakahata S, Sato R, Kanai A, Nakano M, Chinen Y, Maegawa-Matsui S, Matsumura-Kimoto Y, Takimoto-Shimomura T, Mizuno Y, Kuwahara-Ota S, Kawaji Y, Taniwaki M, Inaba T, Tashiro K, Morishita K, Kuroda J. BRD4-regulated molecular targets in mantle cell lymphoma: Insights into targeted therapeutic approach. *Cancer Genomics Proteomics.* 2020 Jan-Feb;17(1):77-89. doi: 10.21873/cgp.20169. (血液内科学との共同研究) (IF= 3.220)

IV 学会発表 (国内学会での一般演題は記載しない)

V 研究助成 (競争的研究助成金)

総額 50 万円

財団等からの助成

代表 (総額)・小計 50 万円

1 一般社団法人日本血液学会 研究助成

令和 2 (2020) 年度

難治性 B 細胞リンパ腫における治療抵抗性の分子機構解明: 長鎖非コード RNA PVT1 キメ

ラ，遺伝子内エクソン再配列，連結遺伝子の解析と臨床応用
助成金額 50 万円